3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
29
Neoplasms
4
Renal Insufficiency
3
Recurrence
3
Neoplasms, Plasma Cell
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Paraproteinemias
2
Neoplasms by Histologic Type
2
Immunoglobulin Light-chain Amyloidosis
2
Blood Protein Disorders
2
Purpura
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Nausea
1
Natural Killer/T-cell Lymphoma
1
Monoclonal Gammopathy of Undetermined Significance
1
Macroglossia
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lymphadenopathy
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Hepatomegaly
1
Hematologic Neoplasms
1
Gastrointestinal Hemorrhage
1
Diarrhea
1
Interventions
Cyclophosphamide
178
Cytarabine
110
fludarabine phosphate
102
Methotrexate
98
Busulfan
90
Filgrastim
80
Rituximab
72
Peripheral Blood Stem Cell Transplantation
69
Cyclosporine
60
Radiotherapy
57
Etoposide
57
Mycophenolic Acid
56
Antilymphocyte Serum
56
fludarabine
55
Tacrolimus
55
Vincristine
47
Whole-Body Irradiation
44
Melphalan
42
Dexamethasone
39
Granulocyte Colony-Stimulating Factor
38
sargramostim
34
Methylprednisolone
34
Alemtuzumab
34
Daunorubicin
33
Imatinib Mesylate
32
Mercaptopurine
28
Prednisone
26
Idarubicin
26
Doxorubicin
25
Leucovorin
24
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Leukemia
×
isatuximab
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts